Untitled Document

For information: Marc Galanter, M.D., Director, Division of Alcoholism and Drug Abuse, Department of Psychiatry, NB20N28, NYU School of Medicine, 550 First Avenue, New York, NY 10016. Phone: (212) 263-6960 Fax: (212) 263-8285. Further information on our programs is available on our center website http://www.med.nyu.edu/substanceabuse.

The magnitude of the alcohol and drug abuse problem today is well-documented. Eighteen percent of the population experiences a substance use disorder at some point in their lives, and the cost of addictive illness to the public is calculated at $246 billion per year in health care and lost work. Furthermore, at least 20% of patients in general medical facilities and 30% in general psychiatric units present with such problems, many of which go undiagnosed -- in some settings, many more. When the sequelae of addiction such as cirrhosis, psychopathology, trauma, and infection are present, they may receive proper medical attention; patients' primary addictive problems often go untreated.

Nonetheless, important advances are being made in the addiction field. Basic mechanisms in relation to receptors, membrane chemistry, and genetic transmission have been elaborated. Public awareness has been aroused so that Substance Abusers seek help earlier, when treatment can be administered more effectively. New treatment concepts, both pharmacologic and psychosocial, have made recovery a possibility for the majority of alcohol and drug abusing patients. Furthermore, the health community has been alerted to the need for early diagnosis and provision of comprehensive care.

The addiction field has moved toward maturation, and it is essential that the trainees in medical teaching centers be exposed to faculty experts in the addictions. In order to develop a cadre of educators and researchers, a sequence of training for medical students, residents, allied health professionals, and fellows has been developed within academic medical centers. NYU has led the nation in this process in developing the field of addiction psychiatry in organized medicine.

Research into addictive illness has been expanded so that emerging concepts in etiology and treatment will be introduced into the medical mainstream. Here, too, the Division at NYU has been a leader in Substance Abuse research. Particularly important in this regard has been the leadership of Robert Cancro, M.D., as Chair of the Department of Psychiatry, and Manuel Trujillo, M.D. as Director of Psychiatry at Bellevue Hospital.

This evolution was formally recognized by organized medicine in the establishment of certificates of added qualification in addiction psychiatry, and in the formal fellowship training process.

The purpose of the Division of Alcoholism and Drug Abuse at NYU is to implement new ideas in training, research and clinical care, and to establish a model for similar programs nationwide. It is uniquely equipped to do so with its extensive facilities and broad-based faculty. Furthermore, it is strongly supported in this mission by one of the country's leading departments of psychiatry and its leading academic medical center.

This investment in resources and innovative approaches has led to the Division receiving the Gold Achievement Award of the American Psychiatric Association, "In recognition of outstanding achievements in the development of a comprehensive Substance Abuse program that provides innovative models of treatment for singly and dually diagnosed multi-cultural individuals."

Addictive illness has been designated as a major academic and clinical focus in the NYU School of Medicine. The school employs a large array of facilities that serve as the base for the academic activities of the Division’s faculty. The School's Division was established by the Department of Psychiatry (Dr. Cancro, Chairman) in 1987, and consists of the following components:

A network of coordinated clinical care, research, and training has been established within the following seven programs of the Bellevue Hospital Center's Substance Abuse Division (Dr. Galanter, Divisional Director). The Division is a component of the Hospital's Department of Psychiatry (Dr. Trujillo, Director). Staffed by NYU faculty, they reflect collaboration between the Medical School, the City's Health and Hospitals Corporation, and State agencies. Because of this, it has been possible to develop a rich, multimodality setting in which clinical and academic work can be conducted.

The Dual Diagnosis Unit (Dr. Ross) is a 27-bed unit that was developed specifically for the rehabilitation of patients diagnosed for both general psychiatric and addictive disorders. It employs a behavioral treatment model combined with peer management techniques, and psychoeducational programs tailored to this population. The relative impact of these treatment approaches has been evaluated and studies have been conducted on the epidemiology and prognostic implications of syndromes observed among these patients. This unit serves as a principal site for training of fellows in addiction psychiatry.

The Chemical Dependency Outpatient Unit (Dr. Miescher) with 14,000 visits annually, begins treatment with an intensive period of engagement into ambulatory care, followed by outpatient group therapy and counseling. The program maintains close ties to facilities in the community and to the Bellevue Hospital Shelter for the homeless and has developed special treatment approaches to the homeless alcoholic. The character of socialization among this latter population is being evaluated.

The Chemical Dependency Inpatient Unit (Dr. Hayden) is a 20-bed service that provides both short-term detoxification and long-term rehabilitation. It maintains a full day program of group and milieu therapy, in addition to educational activities and Alcoholics Anonymous meetings. Studies on this unit have focused on the impact of cognitive impairment on rehabilitation, correlates of social and psychiatric deficits in disadvantaged populations, and the outcome of referral to long-term rehabilitation modalities. Dr. Pettrone is responsible for general medical care on this unit.

The Methadone Maintenance Treatment Program (Drs. Maslansky and Sellers) provides intensive medical and psychiatric treatment, as well as ongoing drug counseling, for 350 patients. In addition, a special therapeutic and counseling program, Children of Substance Abusers, addresses the needs of collaterals of these patients. Many of its patients were admitted because of their unique diagnostic and treatment needs, given the specialized care available at this facility. The program is actively involved in AIDS research activities at the Medical Center, including studies on physiologic and behavioral correlates of seroconversion, sexual behavior and physiology in HIV positive patients.

The Recovery Program (Dr. Mizray) is a model ambulatory treatment service for singly and dually diagnosed patients. Both ante- and postpartum patients and patients who have been hospitalized for sequelae of substance dependence are admitted, with referrals made from relevant hospital units. Induction into treatment occurs through intensive peer-support, and principles of the therapeutic community, modified to the hospital setting, are applied. The program is dedicated to the assessment of innovative treatment for addiction in the general hospital.

The Continuing Treatment Program is a halfway house for the dually-diagnosed. It was developed specifically for homeless patients as an alternative to long-term hospitalization or residence in shelters and welfare hotels. It includes an intensive therapeutic program based on self-help modalities and directed at reintegration into community living. The program provides a model for rehabilitation by establishing continuity of care between hospital-based and community services.

The Centralized Intake Program was established in order to provide evaluation, consultation, and liaison for substance-abusing patients in the Bellevue catchment area, and in the Hospital’s services. It serves to integrate the Hospital’s addiction treatment units and to provide a basis for evaluation of the best matching of patients to respective treatment efforts.

Since its inception, the NYU Division has worked closely with the WHO Programme on Substance Abuse (Geneva), Division of Treatment and Care. These efforts have focused on the development of cross-national initiatives to adapt medical training to a diverse group of countries, and to effect technology transfer of both new and long-demonstrated treatments to other national settings. The Division has organized meetings and publications for an international audience in this capacity. Recent projects include consultation on medical education, and on evaluation of treatment on a cross national basis. Dr. Galanter is responsible for the Substance Abuse Division of our WHO Collaborating Center (Dr. Laska, Director), located at our Nathan Kline Institute.

These facilities include a practice suite for ambulatory treatment of patients by the faculty, as well as for clinical research trials. Patients may also be admitted to the NYU Tisch University Hospital for inpatient care.

This national Center was established in order to serve as an informational base for training activities among postgraduate training programs and to set standards for the education of fellows in psychiatry, medicine, and other specialties. It has a National Advisory Committee of leading academic figures in the Substance Abuse field and has coordinated activities for a multi-specialty national consortium on postgraduate training. Its activities include the operation of a Consortium of national organizations in the addiction field, with liaison to certifying bodies and to federal agencies in the addiction field. The Center, funded by the Scaife Family Foundation, maintains a comprehensive body of information on all addiction fellowships available in its published brochure and on its web site, http://www.med.nyu.edu/substanceabuse.

This research center (Dr. Galanter) was established to undertake projects on spirituality and its role in recovery from psychiatric illness. It involves initiatives such as evaluating this issue in depressed college students and in training psychiatrists to deal with empirical evidence regarding alternative and complementary medicine techniques.

Department of Veterans Affairs New York Harbor Healthcare System (DVA NYHHS) Addiction Services and Medication Development Program

The Department of Veterans Affairs New York Harbor Healthcare System addiction services (Dr. Casadonte) include both inpatient and ambulatory treatment facilities for detoxification and rehabilitation of alcoholic and drug abusing patients as well as research trials. These inpatient/outpatient programs, with the VA Psychiatry Department, serves as the locus for affiliated teaching and research functions of the Division.

The VA is also the site of a NIDA/VA Center (Dr. Rotrosen) for the development of new medications for the treatment of addiction. This major facility works in collaboration with other major research centers in addiction as part of a national collaborative initiative. Studies range from developmental preclinical research to clinical trials and focus on issues such as craving, withdrawal, and toxicity. The VA hospital maintains a collaborative research fellowship program for post residency physicians with The Rockefeller University.

Research collaborations include: pharmacokinetics and analytical chemistry at the Nathan Kline Institute (NKI); positron emission tomography (PET) studies at the Brookhaven National Laboratories; data management and data analysis at NKI; quantitative EEG and evoked potential studies with the NYU Brain Research Laboratory at Bellevue; and magnetic resonance (MRI) imaging, functional MR and MR spectroscopy studies with the Center for Advanced Brain Imaging at the Nathan Kline Institute.

The Institute (Dr. Cancro, Director) has ongoing projects on service delivery research, alternative strategies for payment, and organization of and cost-benefit analyses of services. The Center pursues a program of research that studies the public sector systems that impact persons with severe mental illness (SMI). It conducts research with direct relevance to policy formation, program design and cross-agency coordination in matters pertaining to the care, well-being and livelihood of persons diagnosed with SMI factors that affect the course of rehabilitation. The WHO Center’s Addiction Division (Dr. Galanter) relates to cross-cultural, educational, and research foci.

Carole Siegel, Ph.D. and Kim Hopper, Ph.D., conduct a program of research in the Center concerning the problems of persons who have both mental illness and abuse chemicals. Mary Jane Alexander, Ph.D., is the director of this Core and an investigator in mail surveys to community service directors, a site study of the dually diagnosed among individuals using mental health services, and validation of screens for dual disorders in treatment settings.

Other studies at NKI on Substance Abuse include: the pharmacokinetics and pharmacodynamics of cocaine and metabolites in pregnancy, and a serotonergic challenge in Substance Abuse; predisposition to drug abuse and aggressive behavior; effect of ibogaine on drug-induced behavior and brain function, and the effect of nicotine on neurotransmitter release. Studies also examine the multiplicity of reward mechanisms, in particular differences between the effects of nicotine and those of cocaine. They are designed to identify nicotine-specific effects on dopamine release, and identify the mechanisms involved in the nicotine effects on reward versus the nicotine effects on cognition.

Located at the Nathan S. Kline Institute (Drs. Siegel and Hopper) CSIPMH is a multidisciplinary team of researchers, policy makers, practitioners, providers and recipients of mental health service who develop research within the context of a rigorous research program, influenced by the requirements of a public mental health system. Their goal is to promote recovery in target populations, seek systems integration, enable persons with mental illness to participate fully in community living, and identify innovative mental health treatments that are demonstratively effective and can be widely replicated.

The NIDA-supported Postdoctoral Training Program in Research on Abused Drugs was established in 1992 and is based in the Department of Psychiatry (Drs. Simon and Carr). A group of six faculty members, with active research programs in the study of drugs of abuse, serve as preceptors of research trainees and operate a didactic program tailored to meet individual needs. The research areas of participant laboratories in this multidisciplinary program range from psychophysical studies of electrical brain stimulation reward to the molecular biology of opioid receptors. The research of the faculty is supported by seven funded grants, most of which are related to drug abuse. The Training Program emphasizes laboratory research with research workshops in which trainees and faculty have an opportunity to present and critically discuss work in progress. The didactic component of the Program includes courses at the Medical School and a seminar series in which distinguished researchers in the drug abuse field are invited to speak to Program participants.Current research is focused in two areas: 1) the measurement of brain regional dopamint receptor-mediated signal transduction and 2) effects of subchronic replacement of central insulin, leptin and anorexigenic neuropeptides in food-restricted subjects.

The Brain Research Laboratory (Drs. Prichep, John and Alper) is a division of the department of Psychiatry, broadly concerned with the development and application of new quantitative methods for evaluation of electrophysiological and/or metabolic aspects of brain functions in normal subjects and psychiatric patients. Dr. Alper is engaged in research on brain imaging methods such as topographic mapping of quantitative EEG (QEEG), focusing on effects of cocaine abuse. He organized and directed the First International Conference on Ibogaine and presented data on the use of ibogaine in humans for the indication of opiate withdrawal as well as reviews on the pharmacology of ibogaine and a historical overview of the distinctive advocacy and treatment subculture with which the drug has been associated.

The New York Node of the National Drug Abuse Treatment Clinical Trials Network (Dr. Rotrosen) includes investigators from New York University, The Rockefeller University, Nathan S. Kline Institute for Psychiatric Research, and The Mount Sinai School of Medicine, as well as diverse community settings. Translating new treatments to the broader community is an important public health challenge which is now the focus of the National Drug Abuse Clinical Trials Network launched by the National Institute on Drug Abuse in late 1999. The mission of the Clinical trials Network is (1) to conduct effectiveness studies of behavioral and pharmacological interventions across a wide range of community-based treatment settings in diverse clinical populations, (2) to transfer the results of this research to providers and their patients within the community using science as a vehicle, and (3) to provide policy advice to ensure the delivery of effective treatment to the broadest possible patient population.

Studies have been undertaken (Dr. Marmor) on HIV, the response of drug users to HIV testing and counseling, the utility of needle exchange programs in reducing the spread of HIV among IDUs, and the feasibility of IDUs as research volunteers in HIV vaccine. Currently a clinical trial of an HIV vaccine in IDUs is being done, along with testing another vaccine among men who have sex with men.

The work of this group (Drs. Judith S. and David W. Brook) focuses on a number of the behavioral aspects of diseases and disorders of major interest in public health today, including the global pandemics of tobacco use, drug abuse and AIDS, as well as adolescent violence, using an epidemiological approach and advanced biostatistical techniques to analyze the date. In particular, these researchers and their staff study the psychosocial risk and protective factors of etiological significance in the development of these problematic, risk-taking behaviors, and their sequelae, including interpersonal functioning and coping strategies. They also focus on cultural and ethnic factors related to these behaviors. Studies have included a 27 year on-going study of 900 families in upstate New York, now encompassing three generations in each family. This study has enabled the researchers to assess the intergenerational transmission of risk factors for substance use and abuse from parents to children to grandchildren, looking at behavioral and health issues over three generations.

The research team has also conducted its research studies internationally, in collaboration with colleagues in Columbia, South America, and South Africa. The team studied 3,000 families in Colombia to assess the relationship of ethnicity and cultural factors to the psychosocial risk and protective factors involved in the development of drug use and adolescent violent behavior in that country. These studies have all been funded by Institutes of the National Institutes of Health, in particular the National Institute on Drug Abuse, the National Cancer Institute, and the Fogarty International Center.

Under Dr. Eric Simon, research projects deal with the neurochemistry of receptors and neuropeptides. The Laboratory’s main thrust is an understanding of the structure and functions of the endogenous opioid system, i.e. opioid receptors and endogenous opioid peptides. This laboratory was one of three which simultaneously discovered the opioid receptors in 1973 and has continued to contribute actively to this area. The research is interdisciplinary, ranging from molecular to behavioral aspects of the problem.

One interest is the characterization of the major types of opioid receptors, mu, delta and kappa. To this end they have purified to homogeneity the mu binding site from bovine brain. Recently, they succeeded in reconstituting the purified mu binding protein in liposomes, with pure G-proteins. This results in restoration of selective GTP-sensitive, high affinity mu agonist binding and mu specific stimulation of GTPase activity. They are also studying receptor regulation by phosphorylation and sequestration, the nature of the sugar moieties of this glycoprotein by mass spectrometry in collaboration with Dr. Tom Neubert at the Skirball Institute. Finally, the laboratory is involved in determination of promoter sites of the human mu receptor gene and the regulation of gene expression.

The center (Dr. De Leon) conducts systematic research on refining techniques and improving the effectiveness of treatment in TCs. In addition, it focuses on settings such as mentally ill chemical abusers in community residences, adolescent Substance Abusers in residential TCs, and criminal offenders in corrections facilities. It has undertaken a comprehensive program to study treatment process in therapeutic community-oriented treatment programs.

North Shore University Hospital's Drug Treatment and Education Center (John Imhof, Ph.D.) is located in Manhasset, Long Island. It provides a wide range of diagnostic, treatment and rehabilitation services for the addicted, and serves as a training site for medical students, residents and a PGY-V fellowship in Substance Abuse. The Center also serves as editorial headquarters for the J Substance Abusee Treat, a quarterly, international, interdisciplinary publication. The Journal has become a primary source of treatment literature for Substance Abuse clinicians throughout the United States and abroad.

The School of Nursing of NYU has an active academic program in Substance Abuse (Dr. Naegle) in both teaching and research. With support from a federal faculty development award and New York State foundation support, the program has developed nursing curriculum nationally and carries out educational activities in Division clinical services and other allied facilities.

This division of the Department of Medicine is headed by Dr. Marc Gourevitch. It deals with Substance Abuse patients on medical services, and addresses cost/benefit issues of integrated medical and addiction treatment.

Funding for the academic projects has been provided by the National Institute on Drug Abuse, the Center for Substance Abuse Treatment, the National Institute of Mental Health, the Veterans Administration, National Institute on Allergy and Infectious Diseases, New York State Office of Mental Health, the Scaife Family Foundation, the JM Foundation, the Bodman Foundation, the Langeloth Foundation, the Robert Wood Johnson Foundation, and the Macy Foundation.

The Division has undertaken a special research initiative to develop and evaluate integrated services for the homeless and the dually diagnosed (Dr. Dermatis). Divisional services have been carefully designed to provide continuity of care in this project in order to examine the efficacy of creative models for care within the general hospital system. Emphasis is placed on an intensive self-help model in order to instill patients in an orientation toward abstinence and identification with their peers. The program is designed to serve as a model for other inner-city facilities dealing with similar populations. A behavioral treatment paradigm has been instituted in the operation of the residential dual diagnosis units so as to modify established pathologic patterns with specific reference to securing the remission of acute psychiatric symptoms and training for relapse prevention. This model, adapted from established paradigms in the addiction and behavior therapy fields, employs peer assessment and token economy techniques. Fellows in addiction psychiatry, in particular, have been involved in these studies.

Research into the nature of alcoholism and homelessness among patients admitted to our alcoholism services have yielded better understanding of the impact of psychological and social pathology and cognitive deficits on treatment outcome.

In addition, studies on the nature of psychiatric symptom remission and exacerbation with drug use have further clarified diagnostic and treatment problems in this population.

The Division has undertaken a long-term project to develop techniques for the management of Substance Abusers in office practice, using family and peer supports. This approach, called Network Therapy (Dr. Galanter), has been demonstrated to serve as an effective vehicle for engaging patients in treatment and sustaining abstinence. We have undertaken standardization of the technique and an outcome study on this approach. Educational techniques for house staff and professional staff of the clinical services employing this modality are ongoing as well. Applications are also being investigated for this technique to concurrent pharmacotherapy. Thus, the Division is involved in years 6-9 of NIDA funding of Network Therapy, focusing now on the approach in combination with buprenorphine treatment for heroin addiction.

In collaboration with the World Health Organization, the Division is developing improved techniques for standardizing treatment across nationalboundaries and for effecting technology transfer for new treatments. This project is related to the development of advanced medical educational programs, particularly at the fellowship level.

Attention deficit hyperactivity disorder, characterized by hyperactivity, disorganization,impulsivity, emotionality, unstable personality, fidgetiness, and inability to relax has been reported as a co-morbidity effecting 10% to 40% of various cocaine-dependent populations. Lesser known, however, is the fact thatcocaine modified these symptoms making it more difficult to identify ADHD symptomatology. Dr. Castaneda has studied the effect of stimulants as treatments for cocaine abusers with ADHD.

A variety of investigations have been carried out into the impact of zealous groups on the psychology and drug use of members. These include studies on institutionally-based self-help treatment, Alcoholics Anonymous, peer-led community groups, and spiritually-oriented movements for recovery from mental illness and addiction. These models are being applied in the Division's ambulatory programs.

The Division is also the locus of publication of a number of serials. These include the annual book series, Recent Developments in Alcoholism (Plenum Publishing), an annual scholarly review jointly sponsored by the American Society of Addiction Medicine and the Research Society on Alcoholism; and Substance Abuse (Haworth Medical Press), a peer review journal of the Association for Medical Education and Research in Substance Abuse. Substance Abuse presents research and educational articles to a national and international audience. The Editorial Office of the American Psychiatric Press Textbook of Substance Abuse Treatment, a national standard, is also located here.

In addition, faculty are on Editorial Boards of numerous journals including The American Journal on Addictions, Journal of Addictive Diseases, American Journal of Drug and Alcohol Abuse, Journal of Substance Abuse Treatment, Psychiatric Quarterly, The Journal of Mental Health Policy and Economics, Advances in Alcohol and Substance Abuse, Alcohol andDrug Research, Brain Research, Journal of Molecular Recognition, and Neurochemical Research.

Medical students and residents are given lectures and seminars in addiction, both in relation to pathogenesis and treatment. Medical students get lectures in the first and second years and weekly supervised clinical and literature exposure as part of their psychiatry clerkship experience during the third year. In addition, students with an interest in addiction can take electives in their first, second, and fourth years.

Students may also participate in the addiction programs of the Walter Reed Society of the School’s Master Scholars Program. The Division conducts specialized training and apprenticeship within this Society, dedicated to increased humanism and professionalism in medical training.

In the residency program, seminars and case conferences are conducted in each postgraduate year. The attempt is made to provide house staff with an understanding of the clinical science underlying addiction and then, in the context of case conferences and clinical supervision, to integrate this material into addressing the needs of patients on their respective training services. Elective experiences are offered, in particular, in the PGY IV year, both for NYU residents and for selected residents from other training programs. These experiences may be related to subsequent participation in the PGY V-VI fellowship program.

Faculty of the Division are involved in a collaborative venture with Internal Medicine to provide an innovative model for training of residents and fellows. Training in both the spiritually oriented AA approach, combined with the biomedical and psychological models, are used in didactic sessions for house staff so they can better understand the treatment of addicted patients. A manual for faculty and trainees with related audio-visual aids has been prepared, and the project is being evaluated for broader distribution with support from the Macy Foundation.

A specialized program for training residents and Fellows in Network Therapy has been developed under a grant from the National Institute of Drug Abuse. The program provides lectures and supervision of residents on Network Therapy. The modality employs family and peer supports in order to engage addicted patients in treatment, establish abstinence, and prevent relapse. This undertaking is designed to assure house staff and fellows of needed skills in managing Substance Abuse in office practice. It is currently being applied in a controlled study examining the role of enhanced social supports in improving the outcome for short-term buprenorphine maintenance.

The Substance Abuse Postgraduate Medical Fellowship program was designed to provide high quality clinical care; train teaching and research faculty for medical centers in the future; and conduct investigations into the etiology and treatment of addictive illness. Fellows serve as faculty for two years at the School of Medicine and contribute to the development of the field of Substance Abuse in the same way that fellows have done in earlier decades in subspecialty areas such as cardiology or endocrinology. Remuneration is at the level of an attending physician. Since their establishment in 1998, APA awards for leadership in American Psychiatry have been received by ten of the NYU Addiction Psychiatry Fellows. Training components include:

biochemistry, pharmacology, epidemiology, social theories, genetic models, behavioral conditioning models

During this two-year program following the residency, fellows rotate on both inpatient and outpatient Divisional units, where they evaluate and treat patients under close faculty supervision. This includes teaching rounds, individual supervisory sessions, a clinical and research practicum, and exposure to ongoing faculty research. Didactic work is organized around a weekly seminar, which continues throughout the two-year training period. The seminar includes both research methodology (Dr. Dermatis) and academic readings on addiction. Each fellow conducts an independent research project which is submitted for publication prior to completion of the program. Work on this project begins in the first year and is supported by close faculty supervision throughout, including instruction in research methodology and techniques of data analysis. Research publications of the fellows are listed below:

Barbara Bartlik (M.D., Albert Einstein College of Medicine), 1987-89, (Bartlik B, Galanter M, Angrist B: Dimenhydrinate addiction in a schizophrenic woman. J Clin Psychiatry 50:476, 1989)

Gregory Bunt (M.D., NYU School of Medicine), 1987-89, (Bunt G, Galanter M, Lifshutz H, Castaneda R: Cocaine/"crack" dependency among psychiatric patients. Am J Psychiatry 147:1542-1546, 1990)

Merrill Herman (M.D., Cornell University), 1987-89, (Herman M, Galanter M, Lifshutz H: Homelessness in patients with combined Substance Abuse and psychiatric disorders. Am J Drug Alcohol Abuse 17:415-422, 1991)

Anthony Kim (M.D., Columbia University), 1988-90, (Kim A, Galanter M, Castaneda R, Lifshutz H, Franco H: Crack use and sexual behavior among psychiatric inpatients. Am J Drug Alcohol Abuse 18:235-246, 1992)

Paul Fritz (M.D., Columbia University), 1989-91, (Fritz P, Galanter M, Lifshutz H, Egelko S: Developmental risk factors in postpartum women with positive urine toxicologies for cocaine. Am J Drug Alcohol Abuse 19:187-197, 1993)

Mark Wallace (M.D., University of Louisville), 1989-91, (Wallace M, Galanter M, Kraskinski K, Lifshutz H: Women at high risk of HIV infection from drug use. J Addict Dis 12:77-86, 1993)

Charles Silberstein (M.D., Albert Einstein College of Medicine), 1990-92, (Silberstein C, Galanter M, Marmor M, Lifshutz H, Krasinski K, Franco H: HIV-1 among inner-city dually diagnosed inpatients. Am J Drug Alcohol Abuse 20:101-113, 1994)

Denise Szczucki (M.D., Penn State), 1991-93, (Szczucki D, Galanter M, Lifshutz H, Hoven C, Moore R: Drug use and psychiatric hospitalization among the homeless. Am J Addict 3:115-121, 1994)

Steven Katz, (M.D., NYS/Sackler School), 1991-93, (Katz S, Galanter M, Lifshutz H, Maslansky R: The impact on behavior of notifying methadone patients of their serostatus. Am J Alcohol Drug Abuse 21:37-46, 1995)

Jennifer Goldstein-Michaels, (M.D., NYU School of Medicine), 1991-93, (Michaels J, Galanter M, Resnick R, Marmor M, Lifshutz H, Perrone R: Community-based heroin addicts who turn to experimental treatment rather than conventional care. J Addict Dis 14:33-42, 1995)

Laurence Westreich (M.D., University of Minnesota), 1992-94, (Westreich L: A modified therapeutic community for the dually diagnosed. J Subst Abuse Treat 13:1-4, 1997)

Jorge Leal, (M.D., NY Medical College), 1992-94, (Leal J, Galanter M: The use of contingency contracting to improve outcome in methadone maintenance. J Subst Abuse Treat 16:155-167, 1995)

Lisa Goldfarb, (M.D., Columbia), 1993-95, (Goldfarb L, Galanter M, McDowell D, Lifshutz H, Dermatis H: Medical student and patient attitudes toward religion and spirituality in the recovery process. Am J Drug Alcohol Abuse 22:549-561, 1996)

David McDowell, (M.D., Columbia), 1993-95, (McDowell D, Galanter M, Goldfarb L, Lifshutz H: Spirituality and the treatment of the dually diagnosed: an investigation of patient and staff attitudes. J Addict Dis 15:55-68, 1996)

Robert Stockfish, (M.D., UMD New Jersey), 1993-95 (Stockfish R, Galanter M, Lifshutz H: Trends in dual diagnosis patients. Am J Addict 4:355-356, 1995)

Daniel Mierlak, (M.D., Ph.D., SUNY), 1995-97 (Mierlak D, Galanter M, Spivack N, Dermatis H, Jurewicz E, De Leon G: Modified therapeutic community treatment for homeless dual diagnosed men: who completes treatment? J Subst Abuse Treat 15:117-121, 1998)

Steven Taylor, (M.D., Howard), 1994-95 (Taylor SM, Galanter M, Dermatis H, Spivak N, Egelko S: Dual diagnosed patients in the modified therapeutic community: does a criminal history compromise adjustment to treatment? J Addict Dis 16:32-38, 1997)

David Krakow, (M.D., Hahnemann University), 1996, (Krakow DS, Galanter M, Dermatis H, Westreich LM: HIV risk factors in dually diagnosed patients. Am J Addict 7:74-80, 1998)

Tania Taubes, (M.D., Cornell University), 1995-97, (Taubes T, Galanter M, Dermatis H, Westreich L: Crack cocaine and schizophrenia as risk factors for PPD reactivity in the dually diagnosed. J Addict Dis 17:63-74, 1998)

Daniel Leal, (M.D., University of Texas) 1995-97, (Leal D, Galanter M, Dermatis H, Westreich L: Correlates of protracted homelessness in a sample of dually diagnosed psychiatric inpatients. J Subst Abuse Treat 16:143-147, 1999)

Aaron S. Metrikin (M.D., University Johannesburg), 1997-99, (Metrikin AS, Galanter M, Dermatis H, Bunt G: Somatization, anxiety, and depression in a drug free residential therapeutic community. Am J Addict 12:60-70, 2002)

Stephen Gilman (M.D., University of Pittsburgh), 1998-00 (Gilman S, Galanter M, Dermatis H. Methadone Anonymous: a 12 step program for methadone maintained heroin addicts. J Subst Abuse Treat 22:247-256, 2001

Samuel Glazer (M.D., Cornell University), 1998-00, (Glazer SS, Galanter M, Megwinoff O, Dermatis H, Keller DS: The role of therapeutic alliance in network therapy, a family and peer support-based treatment for cocaine abuse. Subst Abus 24:93-100, 2003

Petros Levounis (M.D., Medical College Pennsylvania), 1998-00, (Levounis P, Galanter M. Dermatis H, Hamowy A, De Leon G: Correlates of HIV transmission risk factors and considerations for interventions in homeless, chemically addicted and mentally ill patients. J Addict Dis 21:61-72, 2002)

Steven Lee (M.D., University of Pennsylvania) 1999-01, (Lee S, Galanter M, Dermatis H, McDowell D: Circuit parties and patterns of drug use in a subset of gay men. J Addict Dis 24:47-60, 2003)

Michael Sobel (M.D., NYU School of Medicine) 1999-01, (Sobel M, Galanter M, Dermatis H: Consultation on Substance Abuse patients in the general hospital)

Ramon Solkhah (M.D. NY Medical College) 1999-01 (Solkhah R, Galanter M, Dermatis H, Daly J, Bunt G: Spiritual orientation among adolescents in a drug-free residential therapeutic community. Am J Drug Alcohol Abuse, in press)

Peter Farol (M.D. Columbia University) 2000-02 (Farol, Galanter, Dermatis: Client satisfaction in a residential modified therapeutic community program for dually diagnosed patients)

Lydia Fazzio (M.D., Tufts University), 2000-02, (Fazio L, Galanter M, Dermatis H, Levounis P: Evaluation of medical student attitudes toward Alcoholics Anonymous. Subst Abus 24:175-185, 2003)

Stephen Ross (M.D. UCLA School of Medicine), 2000-02, (Ross S, Dermatis H, Levounis P, Galanter M: A comparison between dually diagnosed inpatients with and without Axis II co-morbidity and relationship to treatment outcome. Am J Drug Alcohol Abuse 29:263-279, 2003)

Brealyn Sellers (M.D., University of Tennessee), 2001-03. (Sellers MB, Galanter M, Dermatis H, Nachbar M: Enhancing physicians’ use of Alcoholics Anonymous: internet-based training. J Addict Dis, in press)

Marjorie Waldbaum (M.D., Albert Einstein College of Medicine) 2001-03. (Waldbaum M, Galanter M, Dermatis H, Greenberg W: A survey of addiction training in child and adolescent psychiatry residency programs. Acad Psychiatry, under review)

Current Fellows: Alex Horowitz (M.D., Rush Medical College), Tina James (M.D., Ohio State University), Michelle Widlitz (M.D., Sackler School of Medicine) 2003-2005; Romulo Aromin, Jr, (M.D., Tomas University, Philippines), Elizabeth Cho (M.D., Columbia University), and Mary Paizis (M.D., State University of New York at Stony Brook), 2002-2004.

Applications for fellowship positions should be addressed in writing to Dr. Galanter (Department of Psychiatry, NYU School of Medicine, 550 First Avenue, New York, NY 10016: Fax # 212-263-8285), preferably before November 1 of the year preceding the July 1 starting date of the fellowship. The application should include a letter indicating the physician's interest, and a curriculum vitae. Two letters of recommendation should be forwarded by residency teaching faculty at the same time.

The Division conducts a number of training programs for psychologists (Dr. Cohen). At the most junior level, the Research Assistant Program is a training opportunity offered to students matriculated in either undergraduate or graduate (M.A. or Ph.D.) psychology programs, who are seeking a supervised experience in a clinical research setting.

The Externship Program provides part-time training for second and third year graduate students matriculated in psychology doctoral programs, and is geared toward development of competence in psychological assessment.

An Internship rotation is part of the full-time predoctoral level training program of the Division of Psychology at the Medical School (Drs. Vasquez, Cohen). The NYU-Bellevue internship is accredited by the American Psychological Association, and is offered to students matriculated in doctoral programs in Clinical and School Psychology.

The Psychology Fellowship Program, also in conjunction with the Division of Psychology, is an advanced training placement for psychology graduate students who have completed an internship, or persons who have completed their Ph.D. program. Fellows are instructed by the Division's senior psychologists in more sophisticated clinical skills and participate in ongoing research in collaboration with the Division's principal investigators.

Divisional Grand Rounds is a monthly lecture series for visiting speakers of national prominence, and is open to all Medical Center staff. Other training seminars are directed at social work and counseling staff specifically. Additional specific programs include a variety of continuing medical education programs conducted in conjunction with the Medical Center. In addition programmatic involvement is carried out with several national professional and scientific organizations in the addiction field, such as the American Academy of Addiction Psychiatry, the Association for Medical Education and Research in Substance Abuse, and the American Society on Addiction Medicine.

Clinical services at Bellevue originated in 1736 as part of New York City's "Public House of Correction, Workhouse and Poorhouse." A special unit for alcoholics was created in 1892, and a unit for housing the insane was opened in 1898. In 1985, the psychiatric units were transferred to a new Bellevue Hospital building. Bellevue's name, recognized around the world, is often thought to be synonymous with the hospital's Psychiatric Services because of the leading role they have played in the institution's development and in Academic Psychiatry nationally.

As Chairman of the Department of Psychiatry, Robert Cancro, M.D., has strengthened the department's academic components on both the undergraduate and postgraduate levels. Under his leadership, affiliations have been established throughout the state hospital system, in particular with the Nathan S. Kline Institute for Psychiatric Research, and Rockland, Manhattan, and Kirby Psychiatric Centers.

A collaboration with Brookhaven National Laboratory has resulted in research activity in positron emission tomography (PET). The Department has an affiliated Psychoanalytic Institute on its premises. In 1987, Dr. Cancro established the Division of Alcoholism and Drug Abuse within the Department, unifying existing teaching and research facilities and designating new ones. This represented a major initiative for the School of Medicine in research, teaching, and patient care.

The history of the School of Medicine spans more than two centuries. Clinical instruction was started in Bellevue Hospital in 1847, and in 1861 Bellevue Hospital Medical College was founded when a College building was erected on the hospital grounds. The medical school became an integral part of New York University in 1898.

Most of the student teaching is carried out in the Bellevue Hospital Center. It was founded in 1736, and is the oldest continuously operating hospital in the United States. The current facility is a modern 25-story building, opened in 1975, with 1,171 beds. Tisch University Hospital, opened in 1963, is an acute-care general hospital with 726 beds that admits patients from around the world. Another hospital that has been integrated into the School of Medicine is the New York Veterans Administration Medical Center, an 851-bed general care facility located next to Bellevue Hospital Center.

The Nathan S. Kline Institute for Psychiatric Research conducts basic scientific, applied, and health service research. It is one of six World Health Organization Collaborating Centers in the United States.

Listed below are selected publications by Divisional faculty which appeared, or are in press, in the last three years. They are selected from those which have a substance abuse focus.

Almoguera-Abad A, Castaneda R, Decastro A, Trujillo M: Superior efficacy of olanzepine in Chinese schizophrenic patients: results of an open laber study. Am J Psychiatry, in press

Alper KR, Lotsof HS, Frenken GMD, Luciano DV, Bastiaana J: Ibogaine in acute opioid withdrawal: an open label case series. Ann N Y Acad Sci 909:257-259, 2000

Alper K, Devinsky O, Westbrook L, Luciano D, Pacia S. Perrine K, Vazquez B: Premorbid psychiatric risk factors for postictal psychosis. J Neuropsychiatry Clin Neurosci 13:492-499, 2001

Andria ML, Simon EJ: Identification of a neurorestrictive suppressor element (NRSE) in the human μ-opioid receptor gene. Molecular Brain Research 91:73-80, 2001

Binienda ZK, Pereira F, Alper K, Slikker W, Ali SF: Adaptation to repeated cocaine administered in rats. Ann N Y Acad Sci 965:172-179, 2002

Brodie JD, Figueroa E, Dewel SL: Treating cocaine addiction: from preclinical to clinical trial experience with γ-vinyl GABA. Synapse 50:261-265, 2003

Brook DW, Brook JS, Zhang C, Cohen P, Whiteman M: Drug use and the risk of major depressive disorder, alcohol dependence, and substance use disorders. Arch Gen Psychiatry 59:1039-1044, 2002

Brook, DW: Ethnicity and culture in the group psychotherapy of Substance Abuse. In D.W. Brook and H.I. Spits (Eds.), Group Therapy of Substance Abuse. New York, Haworth Press, 2002, pp 225-242

Brook DW, Brook JS, Pahl T, Montoya ID: The longitudinal relationship between drug use and risky sexual behaviors among Colombian adolescents. Arch Pediatr Adolesc Med 156:1101-1107, 2002

Brook DW, Brook JS, Richter L. Whiteman M, Arencibia-Mireles O, Masci JR: Marijuana use among the adolescent children of high risk drug-abusing fathers. Am J Addict. 11:95-110, 2002

Brook DW, Brook JS, Rosen Z, Montoya ID: Correlates of marijuana in Colombian adolescents: a focus on the impact of the ecological/cultural domain. J Adolesc Health. 31:286-298, 2002

Brook DW, Brook JS, Whiteman M, Arencibia-Mireles O, Pressman M, Rubenstone E: Coping in adolescent children of HIV-positive and HIV-negative substance abusing fathers.J Genet Psychol 163:5-23, 2002

Brook DW, Brook JS, Rubenstone E, Zhang C, Singer M, Duke MR: Alcohol use in adolescents whose fathers abuse drugs. J Addict Dis 22:11-34, 2003

Brook DW, Brook JS, Rosen Z, De La Rosa M, Montoya ID, Whiteman M. Early risk factors for violence in Colombian adolescents. Am J Psychiatry. 160:1470-1478, 2003

Brook JS, Adams RE, Balka EB, Johnson E: Early adolescent marijuana use: risks for the transition to young adulthood. Psychol Med 32:79-91, 2002

Brook JS, Brook DW, Rosen Z, Rabbitt CR: Earlier marijuana use and later problem behavior in Colombia youth. J Am Acad Child and Adolesc Psychiatry 42:485-492, 2003

Brook JS, Finch S, Whiteman S, Brook DW: Drug use and neurobehavioral, respiratory, and cognitive problems: Precursors and mediators. J Adolesc Health 30:433-441, 2003

Cabeza de Vaca S, Kim G-Y, Carr KD: The melanocortin receptor agonist, MTI, augments the rewarding effect of amphetamine in ad libitum fed and food-restricted rats. Psychopharmacology 161:177-185, 2002

Carr KD: Augmentation of drug reward by chronic food restriction: behavioral evidence and underlying mechanisms. Physiology and Behavior 76:353-364, 2002

Carr KD, Yamamoto N, Omura M, Cabeza de Vaca S, Krahne L: Effects of the D-3 dopamine receptor antagonists, U99194A, on brains stimulation and d-amphetamine reward, motor activity and c-fos expression in ad libitum fed and food restricted rats. Psychopharmacology 163:76-84, 2002

Carr KD, Tsimberg Y, Berman Y, Yamamoto N: Evidence of increased dopamine receptor signaling in food-restricted rats. Neuroscience 119:1157-1167, 2003

Casadonte P: Treatment of opiate dependence with buprenorphine/naloxone in a solo private psychiatry practice. Drug Alcohol Depend 63:24, 2001

Casadonte P: Impact of the FDA LAAM labeling warning on a VA narcotic treatment program in New York City. Drug Alcohol Depend 66:27, 2002

Castaneda R: Treatment with antidepressants and long-acting stimulants of attention deficit disorder in cocaine-dependent adults. Adiciones 3:138, 2001

Castaneda R, Sussman N, Westreich L, Levy R: A review of moderate alcohol intake on the treatment of anxiety and mood disorders. CD ROM, Prous Sciences, 2000

Charney DS, Nemeroff CB, Lewis L, Laden SK, Gorman JM, Laska EM, et al.: National depressive and manic-depressive association consensus statement on the use of placebo in clinical trials of mood disorders. Arch Gen Psychiatry 59:262-270, 2002

Committee on Addictions (GAP) Boyarsky B, Dilts S, Frances RJ, Frosch WA, Galanter M et al.: Responsibility and choice in addiction. Psychiatr Serv 53:707-713, 2002

De Leon G: Therapeutic communities: research-practice reciprocity. In J.L. Sorensen, R.A. Rawson, J. Guydish & J.E. Zweben (Eds.), Drug abuse treatment through collaboration: practice and research partnerships that work. Washington, DC, American Psychological Association, 2003, pp. 17-35

De Leon G. The research context for therapeutic communities in the USA. In J. Lees, N. Making, D. Menzies, and N. Morant (Eds.), Research therapeutic communities. London, Jessica Kingley Publishers, in press

Dermatis H, Guschwan M, Galanter M, Bunt G: Orientation toward spirituality and self-help approaches in the therapeutic community. J Addict Dis, in press

Efferen T, Duncan E, Szyilagy S, Chakrovorty S, A Adams J, Gonzenbach S, Angrist B, Butler P, Rotrosen J: Diminished acoustic startle in chronic cocaine users. Neuropsycho-pharmacology 22:89-96, 2000

Egelko S. Galanter M, Dermatis H, Jurewicz E. Jamison A, Dingle S, De Leon G: Improved psychological status in a modified TC for homeless MICA men. J Addict Dis 21:75-92, 2002

Galanter M, Dermatis H, Keller D, Trujillo M. Network therapy for cocaine abuse: Use of family and peer supports. Am J Addict 11:161-166, 2002

Galanter M, Dermatis H, Calabrese D. Residencies in addiction psychiatry: 1990 to 2000, a decade of progress. Am J Addict 11:192-199, 2002

Galanter M, Brook D: Network therapy. In Brook D, Spitz H (Eds.), Group therapy of Substance Abuse. New York, Haworth Press: 199-202, 2002

Galanter M: Healing through social and spiritual affiliation. Psych Services 53:1072-1074, 2002

Galanter M. Self-help treatment for combined addiction and mental health illness. Reprinted in Focus (APA publication) 1:179-182, 2003

Galanter M, Dermatis H, Resnick RB, Maslansky R, Neuman E: Short term buprenorphine maintenance: treatment outcome. J Addict Dis 22:39-49, 2003

Glazer SS, Galanter M, Megwinoff O, Dermatis H, Keller DS: The role of therapeutic alliance in network therapy, a family and peer support-based treatment for cocaine abuse. Subst Abus 24:93-200, 2003

Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderling J, et al.: Recovery from psychotic illness: a 15 and 25 year international follow-up study. Br J Psychiatry 178:506-517, 2001

Hawke JM, Jainchill J, De Leon G: Post-treatment victimization and violence among adolescents following residential drug treatment. Child Maltreat 8:58-71, 2003

Hopper K, Barrow. Two genealogies of supported housing: implications for outcome assessment. Psychiatr Serv 54:50-54, 2003

Kaufman E, Brook DW. Family Therapy: Other Drugs. In M Galanter, HD Kleber (Eds.) Textbook of Substance Abuse Treatment, Third Edition. Washington, DC, American Psychiatric Press, in press

Kessler RC, Berglund PA, Bruce ML, Koch JR, Laska EB, Leaf PH, Manderscheid RW, Rosenceck RA, Walter EE, Wang PS: The prevalence and correlates of untreated serious mental illness. Heatlh Serv Res 36:987-1007, 2001

Kramer HK, Onoprishvili I, Andria ML, Kayane H, Sheinkman K, Haddad LB, Simon EJ: Delta opioid activation of the mitogen-activated protein kinase cascade does not require transphosphorylation of receptor tyrosine kinases. BMC Pharmacol 2:1-10, 2002

Laska EM, Leber P: If placebo works, could, should or would it be approved for marketing? Chance 15, 2002

Laska EM, Meisner M, Siegel C: Statistical cost-effectiveness analysis of two treatments based on net health benefits. Stat Med 20:1279-1302, 2001

Lee S, Galanter M, Dermatis H, McDowell D: Circuit parties and patterns of drug use in a subset of gay men. J Addict Dis 24:47-60, 2003

Marmor M, Sheppard HW, Donnell B, Bozeman S, Celum C, Buchbinder S, Koblin B, Seage GR III for the HIVNET Vaccine Preparedness Protocol Team: Both homozygous and hererozygous CCR5-Æ32 genotypes are associated with resistance to HIV infection. J Acquir Immune Defic Syndr 27:472-481, 2001

Morgan K, Kressel D, De Leon G, Garvin D, Muehlbach B: Assessing client progress in therapeutic communities: a factor analysis of the client assessment summary and staff assessment summary. J Subst Abuse Treat, in review

Naegle M, Krainovich-Miller B: Shaping the advanced practice psychiatric-mental health nursing role: a futuristic model. Issues in Mental Health Nursing 22:464-482, 2001

Naegle M. Addiction: a global public health challenge for nurses. The Drug and Alcohol Professional 2:11-15, 2002

Naegle M, Ng A, Barron C, Lai TFN: Best practice: topics in review: Alcohol and Substance Abuse. West J Med 176:259-263, 2002

Naegle M. Substance abuse and addiction among registered professional nurses. In JJ Fitzpatrick, P Wilke (Eds.) Psychiatric Mental Health Nursing Research Digest. New York, Springer Publishing: 224-227, 2001

Naegle M: Mental health and substance-related health care. In M Naegle, CE D’Avanzo (Eds.) Addictions and substance abuse: strategies for advanced nursing practice. Saddle River, New Jersey, Prentice Hall Health, 2001

Onoprishvili I, Andria ML, Kramer HL, Hiller JM, Simon EJ. Filamin A: Repeats 19-21 binds to the c-tail of the opioid receptor. Molecular Pharmacology, in press.

Prichep LS, Alper KI, Sverdlov L, Lowalik SC, John ER, Merkin H, Tom M, Howard B, Rosenthal MS: Outcome related electrophysiological subtypes of cocaine dependence. Clin Electroencephalogr: 8-20, 2002

Prichep LS: QEEG profiles of cocaine dependence. Abstracts of the 56th Annual Convention and Scientific Program of the Society of Biological Psychiatry 49(8S), 7#, New Orleans, 2001

Prichep LS: Biomarkers in cocaine addiction: quantitative EEG profile of cocaine dependence. Abstracts of the 63rd Annual Scientific Meeting of the College of Problems of Drug Dependence, Scottsdale, 2001

Reid MS, Prichep L, Ciplet D, O’Leary S, Tom ML, Howard BS, Rotrosen J, John R: Quantitative electroencephalographic studies of cue-induced cocaine craving. Clin Electroencephalogr 34:110-123, 2003

Reid MS, Ciplet D, O’Leary S, Angrist B: Sensitization to the psychosis-inducing effects of cocaine compared with measure of cocaine craving and cue. Am J Addict, in press

Reid MS, Casadonte P, Sanfilipo M, Baker S, Braunstein D, Hitzmann, Montgomery A, Majewska D. Robinson J, Rotrosen J: A placebo control screening trial of olanzapine, valproate or co-enzyme Q10/L-carnitine for the treatment of cocaine dependence. Addiction (submitted as part of the NIDA MDRU Supplement issue), 2003

Resnick RB, Galanter M, Resnick E, Pycha C: Buprenorphine treatment of heroin dependence (detoxification and maintenance) in a private practice setting. J Addict Dis 30:75-83, 2001

Resnick RB, Resnick E: Buprenorphine: a new strategy for reducing demand for heroin. Proceedings: Office of National Drug Control Policy (ONDCP) Symposium: Counter-drug Research and Development, Technologies for the Next Decade 1:72-78, 2001

Sacks S, De Leon G, Sacks JY, McKendrick K, Brown B: TC-oriented supported housing for homeless MICAs. J Psychoactive Drugs 35(3), 2003

Sanfilipo M, Lafargue T, Arena L, Rusinek H, Kushner K, Lautin A, Loneragan C, Vaid G, Rotrosen J, Wolkin A: Fine volumetric analysis of the cerebral ventricular system in schizophrenia: further evidence for multi-focal mild to moderate enlargement. Schizophr Bull 26:201-216, 2000

Sanfilipo M, Lafargue T, Rusinek H, Arena L, Loneragan C, Lautin A, Reiner D, Rotrosen J, Wolkin A: Volumetric measure of the frontal and temporal lob regions in schizophrenia-relationship to negative symptoms. Arch Gen Psychiatry 57:471-480, 2000

Siegel C, Laska E, Haugland G, O’Neill D, Cohen N, Lesser M: The construction of community indexes of mental health and social and mental well being and their application to New York City. Evaluation and Program Planning 23:315-327, 2000. Correction: 24:4:451, 2001

Siegel C, Laska EM, Meisner M: Estimating capacity requirements for mental health services after a disaster has occurred: a call for new data. Am J Public Health, Accepted, 2003

Siegel C, Haugland G, David-Chambers E: Performance measures and their benchmarks for assessing organizational cultural competency in behavioral health care service delivery. Adm Policy Ment Health Accepted, 2003

Siqueira LM, Brook JS: Tobacco use as a predictor of illicit drug use and drug-related problems in Colombian youth. J Adolesc Health 32:50-57, 2003

Tracy K, Weingarten R, Mattison E, Piselli A, Rounsaville B: Moving beyond illness to recovery: the recovery is for everyone grants program (RIFE). Psychiar Rehabil J, in press

Tracy K, Rounsaville B, Carroll K: Psychotherapy of substance dependence. Encyclopedia of Psychotherapy. New York, Academic Press, 2002

Westreich L: Addiction and the Americans with disabilities act. J Am Acad Psychiatry Law 30:355-363, 2003

Westreich L: Turning addiction emergencies into catalysts for change. Curr Psychiatry 12:51-57, 2002

Westreich L: Epidemiology of substance use disorders. Prim Psychiatry 10:65-72, 2002

The Division of Alcoholism and Drug Abuse is a component of the Department of Psychiatry, NYU Medical School, Robert Cancro, M.D., Chairman

Jonathan D. Brodie, M.D.
David W. Brook, M.D.
Judith S. Brook, Ph.D.
Michael Marmor, Ph.D. (Environmental Medicine)
Madeline Naegle, APRN-BC, Ph.D., F.A., A.N. (Nursing)
John Rotrosen, M.D.
Eric J. Simon, Ph.D. (Psychiatry and Pharmacology)
Zebulon C. Taintor, M.D.
Jan Volavka, M.D., Ph.D.

Abel Lajtha, Ph.D.
Carole Siegel, Ph.D.

George De Leon, Ph.D.
Richard Frances, M.D.

Kenneth D. Carr, Ph.D.

Helen Dermatis, Ph.D.
Leslie Prichep, Ph.D.
Kim Hopper, Ph.D.

Lenard Adler, M.D.
Paul P. Casadonte, M.D.
Ricardo Castaneda, M.D.
Richard Resnick, M.D.
Laurence Westreich, M.D.

Kenneth R. Alper, M.D.
Malcolm Reid, Ph.D.

Gregory Bunt, M.D.
Erica Duncan, M.D.
Linda Glickman. Ph.D.
Lisa Goldfarb, M.D.
Marianne Guschwan, M.D.
Jeffrey Guss, M.D.
Lynn Hall, Ph.D.
Francis Hayden, M.D.
Robert Maslansky, M.D.
Nicholas A. Pace, M.D. (Medicine)
Annatina Miescher, M.D.
Stephen Ross, M.D.
Carlotta Schuster, M.D.
Brealyn Sellers, M.D.

Romulo Aromin, M.D.
Elizabeth Cho, M.D.
Sam Glazer, M.D.
Stephen Gilman, M.D.
Alex Horowitz, M.D.
Tina James, M.D.
Militza Mizray, M.D.
Aaron Metrikin, M.D.
Mary Paizis, M.D.
Michael Sobel, M.D.
Michelle Widlitz, M.D.

The following faculty are Directors of the affiliated programs: Carol Bernstein, M.D. (Associate Professor of Psychiatry, Director Residency Training); Ilene Cohen, (Clinical Associate Professor); Psychology; Marc Gourevitch, M.D. (Director of General Internal Medicine); Harold Koplewicz, M.D. (Director of Child and Adolescent Psychiatry); Eugene Laska, Ph.D. (Research Professor; Epidemiology, NKI); Manuel Trujillo, M.D. (Professor of Clinical Psychiatry; Bellevue)